A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeOne Medicines
BeOne Medicines
AstraZeneca
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme LLC
Eli Lilly and Company
Pfizer
Novartis
Alterome Therapeutics, Inc.
Verastem, Inc.
Pfizer
Tizona Therapeutics, Inc
Novartis
Genentech, Inc.
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
Jacobio Pharmaceuticals Co., Ltd.
Bristol-Myers Squibb
Bristol-Myers Squibb
Fate Therapeutics
Genentech, Inc.
Eli Lilly and Company
Genfleet Therapeutics (Shanghai) Inc.
Bristol-Myers Squibb
Hummingbird Bioscience
InventisBio Co., Ltd
Innovent Biologics (Suzhou) Co. Ltd.
Pfizer
GlaxoSmithKline
Fate Therapeutics
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company
NKMAX Co., Ltd.
NKGen Biotech, Inc.
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany
HiberCell, Inc.
Merrimack Pharmaceuticals
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Boehringer Ingelheim
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany